GLP-1 medications can be a strong option for PCOS-related weight loss in adults with overweight or obesity, especially when insulin resistance, central weight gain, or prediabetes are part of the picture. They are not FDA-approved specifically for PCOS, but the 2023 international PCOS guideline says anti-obesity medications including liraglutide and semaglutide could be considered for higher weight in adults with PCOS, alongside active lifestyle intervention and with attention to contraception, dose escalation, side effects, and the likelihood of long-term use.
Comparison Table
| Option | What it is | Where it fits in PCOS | What to know |
|---|---|---|---|
| Wegovy / Wegovy HD (semaglutide) | FDA-approved obesity medication | Strong choice when PCOS is paired with obesity or overweight plus a weight-related condition | Approved for chronic weight management, but not specifically for PCOS. Higher-dose Wegovy HD was approved in March 2026 |
| Zepbound (tirzepatide) | FDA-approved obesity medication; dual GIP/GLP-1 drug | Often attractive when weight loss is the main goal and obesity is present | Not PCOS-specific, but part of the same obesity-treatment conversation and often considered in practice |
| Saxenda (liraglutide) | FDA-approved obesity medication | Older GLP-1 option that guideline writers specifically name in PCOS | Daily injection and generally less convenient than newer weekly options |
| Metformin | Insulin-sensitizing medication | Still common in PCOS, especially with insulin resistance, prediabetes, or cycle issues | Less potent for weight loss than GLP-1s, but often cheaper and more established in PCOS care |
GLP-1s are not "PCOS drugs," but they can still be very useful
GLP-1 drugs are not approved specifically to treat PCOS itself. They are approved for obesity, overweight with certain comorbidities, and in some cases type 2 diabetes or other metabolic conditions. But because many women with PCOS also struggle with obesity, insulin resistance, abdominal weight gain, prediabetes, or metabolic syndrome, these drugs can still be highly relevant.
The 2023 international evidence-based PCOS guideline is fairly clear: anti-obesity medications including liraglutide and semaglutide could be considered for management of higher weight in adults with PCOS as per general population guidelines. It also specifically says clinicians should ensure effective contraception when pregnancy is possible, use gradual dose escalation to reduce GI side effects, and discuss the risk of weight regain after stopping.
Why GLP-1s can make sense in PCOS
PCOS is not just a reproductive issue. For many women it is also a metabolic issue. Weight gain, insulin resistance, and visceral fat can worsen the whole loop: more insulin resistance can drive androgen excess, cycle irregularity, and further weight difficulty. So a medication that meaningfully lowers weight and improves metabolic markers may help more than the scale alone.
A 2025 meta-analysis of randomized trials in women with PCOS found that GLP-1 receptor agonists significantly reduced BMI, body weight, waist circumference, waist-to-hip ratio, and abdominal girth, and also improved several glucose-homeostasis markers compared with metformin or placebo.
A 2026 pilot prospective study of women with PCOS, obesity, and prediabetes reported weight-loss and fertility-related improvements with semaglutide plus metformin, though it was a small study of 20 patients — promising rather than definitive.
Who is the best candidate
The best candidate is usually an adult with PCOS who also has overweight or obesity and has not gotten enough traction from lifestyle measures alone, especially if insulin resistance, prediabetes, fatty liver risk, or central weight gain are part of the picture.
This is not the ideal conversation for someone who is lean with PCOS and primarily dealing with acne, hirsutism, or cycle irregularity without weight-related disease. The better fit is when weight and metabolic dysfunction are driving the clinical picture.
Which GLP-1 is best for PCOS weight loss?
If the goal is strictly maximum weight loss, semaglutide and tirzepatide are usually the most compelling modern options. Wegovy is FDA-approved for chronic weight management, and Wegovy HD was approved in March 2026 as a higher-dose option for additional weight-loss support in eligible adults.
Liraglutide appears directly in the PCOS guideline, which matters because it has older obesity-use experience in this population. But in real-world 2026 practice, many people will be comparing semaglutide or tirzepatide-based obesity treatment because they are weekly and often more compelling on weight-loss efficacy.
Important downsides and cautions
Pregnancy. The PCOS guideline explicitly says clinicians should ensure effective contraception when pregnancy is possible for women taking GLP-1 receptor agonists, because pregnancy safety data are lacking. This is especially relevant in PCOS, where fertility can improve as weight and ovulation normalize.
Side effects and titration. Nausea, vomiting, constipation, diarrhea, and appetite suppression are common enough that the PCOS guideline specifically recommends gradual dose escalation.
Long-term expectations. The guideline also flags likely long-term use and the high risk of weight regain after discontinuation. For many people, obesity treatment is chronic care — not a short course and done.
Compounded shortcuts. In 2026 the FDA has been aggressive about restricting mass-marketed compounded GLP-1 products and warning that it cannot verify their quality, safety, or efficacy the way it does for approved drugs.
How GLP-1s compare with metformin for PCOS weight loss
Metformin is still a core medication in PCOS care, especially around insulin resistance and prediabetes, and it remains more established in many OB-GYN and endocrine workflows. But if the question is which tends to move weight more, GLP-1 drugs generally look stronger. The 2025 meta-analysis found better anthropometric outcomes with GLP-1 receptor agonists than with metformin or placebo.
That does not mean metformin is obsolete. If cost, access, or mild metabolic symptoms dominate, metformin may still be the first move. If obesity and failed prior weight-loss efforts are central, GLP-1 treatment often becomes much more compelling.
Verdict
GLP-1 treatment can be a very good option for PCOS-related weight loss when higher weight and metabolic dysfunction are major parts of the picture. Take it seriously for an adult with PCOS plus obesity or overweight-related complications, especially after lifestyle efforts and simpler medication strategies have not been enough. Do not treat it as a universal PCOS fix, and do not use it casually in someone trying to conceive soon or being funneled toward sketchy compounded products. GLP-1s are not PCOS-specific — but they can be one of the most effective tools for the weight-loss side of PCOS when used thoughtfully.
FAQ
Is semaglutide approved for PCOS?
No. Semaglutide is not FDA-approved specifically for PCOS. It is approved for obesity and certain other uses, and the PCOS guideline says it could be considered for higher weight in adults with PCOS according to general population obesity guidance.
Do GLP-1 drugs help women with PCOS lose weight?
Yes, evidence suggests they can. A 2025 meta-analysis found significant improvements in body weight, BMI, waist circumference, and other anthropometric measures in women with PCOS treated with GLP-1 receptor agonists.
Is Ozempic or Wegovy better for PCOS?
Neither is "for PCOS" specifically. If the goal is weight loss in a woman with PCOS plus obesity, the more relevant question is which obesity-treatment pathway fits her clinical picture and coverage. Wegovy is the obesity-labeled semaglutide product.
Can GLP-1 treatment improve fertility in PCOS?
Possibly, mainly through weight loss and metabolic improvement, but the evidence is still developing. A small 2026 pilot study suggested benefits in women with PCOS, obesity, and prediabetes treated with semaglutide plus metformin, but larger studies are still needed.
Do I need contraception on a GLP-1 if I have PCOS?
Yes, if pregnancy is possible. The 2023 PCOS guideline specifically recommends ensuring effective contraception for women taking GLP-1 receptor agonists because pregnancy safety data are lacking.
Should women with PCOS use compounded semaglutide?
Only cautiously, and only if there is a real reason an FDA-approved product cannot meet the need. FDA says compounded GLP-1 products are not FDA-approved and should generally be reserved for situations where a patient's needs cannot be met by an approved drug.